Gil Roth05.03.12
Charles River Laboratories 1Q12
1Q Revenues: $286 million (flat)
1Q Earnings: $26 million (-16%)
Comments: Research Models and Services was up 6% to $183 million, driven by In Vitro and Avian businesses., for its best quarter since 2008. Preclinical Services dropped 9% to $103 million, with lower sales of biopharmaceutical services due to typically slow starts from large biopharma cients.
1Q Revenues: $286 million (flat)
1Q Earnings: $26 million (-16%)
Comments: Research Models and Services was up 6% to $183 million, driven by In Vitro and Avian businesses., for its best quarter since 2008. Preclinical Services dropped 9% to $103 million, with lower sales of biopharmaceutical services due to typically slow starts from large biopharma cients.